drugset / Trial / NCT03352726

A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects

NCT03352726 ↗

Phase 1 Completed 27 enrolled DBV Technologies
NaSingle-groupOpen-labelOther

Summary

The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.

Timeline

Start
2017-11-24
Primary completion
2018-06-29
Completion
2018-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject DBV712 IHRP Unknown — Other

Indications